Ambrose Kristen
SEC CIK 1856587 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | SVP, CAO | 11.6K | — | $4.93M | 35 | 2022-02-01 | 2026-08-28 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
| 12 | Ambrose Kristen | SVP, CAO | — | $1.98M |
Transactions 35
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-01 16:39 | 2026-08-28 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +5,000 | 11.6K | +75% | $0 | |
| 2026-03-02 | 2026-02-26 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $483.36 | -357 | 6,624 | -5% | -$172.6K | |
| 2026-02-26 | 2026-02-25 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $486.35 | -223 | 6,981 | -3% | -$108.5K | |
| 2026-02-26 | 2026-02-24 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $485.11 | -546 | 7,204 | -7% | -$264.9K | |
| M | 2026-02-19 | 2026-02-17+ | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $484.87 | -2,195 | 8,388 | -21% | -$1.06M |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +1,809 | 10.5K | +21% | $0 | |
| 2026-02-19 | 2026-02-17 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $483.75 | -598 | 9,945 | -6% | -$289.3K | |
| 2026-02-18 | 2026-02-13 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $487.76 | -1,393 | 8,734 | -14% | -$679.4K | |
| 2026-02-12 | 2026-02-10 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $468.41 | -592 | 11.5K | -5% | -$277.3K | |
| 2026-02-12 | 2026-02-11 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $460.43 | -1,376 | 10.1K | -12% | -$633.6K | |
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,250 | 12.1K | +54% | $0 |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $479.61 | -1,241 | 7,845 | -14% | -$595.2K | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $483.28 | -828 | 9,970 | -8% | -$400.2K | |
| 2025-02-26 | 2025-02-25 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $480.95 | -884 | 9,086 | -9% | -$425.2K | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $463.46 | -564 | 11.5K | -5% | -$261.4K | |
| 2025-02-19 | 2025-02-18 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $455.06 | -671 | 10.8K | -6% | -$305.3K | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +2,080 | 12.0K | +21% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $467.98 | -591 | 11.3K | -5% | -$276.6K | |
| 2025-02-12 | 2025-02-11 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $459.83 | -1,376 | 9,953 | -12% | -$632.7K | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,420 | 10.1K | +78% | $0 |
| 2024-04-03 | 2024-04-01 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $418.10 | -225 | 7,740 | -3% | -$94.1K | |
| 2024-04-03 | 2024-04-02 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $419.00 | -240 | 7,500 | -3% | -$100.6K | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $431.79 | -828 | 8,848 | -9% | -$357.5K | |
| 2024-02-27 | 2024-02-26 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $425.70 | -883 | 7,965 | -10% | -$375.9K | |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $422.74 | -591 | 11.1K | -5% | -$249.8K | |
| 2024-02-13 | 2024-02-12 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $420.24 | -1,374 | 9,676 | -12% | -$577.4K | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +4,803 | 9,788 | +96% | $0 |
| 2023-06-01 | 2023-05-30 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $329.82 | -289 | 6,838 | -4% | -$95.3K | |
| 2023-04-04 | 2023-03-31 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $313.74 | -176 | 7,127 | -2% | -$55.2K | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $287.55 | -1,207 | 7,528 | -14% | -$347.1K |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $289.12 | -502 | 8,510 | -6% | -$145.1K | |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +5,516 | 9,012 | +158% | $0 |
| M | 2022-04-27 | 2022-04-25 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | S - Sale | $269.55 | -327 | 3,600 | -8% | -$88.1K |
| 2022-04-05 | 2022-04-01 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | F - Tax | $263.09 | -137 | 3,823 | -3% | -$36.0K | |
| 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Ambrose Kristen | SVP, CAO | A - Grant | $0.00 | +2,566 | 3,960 | +184% | $0 |
Purchase Sale Sale after option exercise All abbreviations